Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Curis Inc

CRIS ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$1.80

▼ -3.74%

Market Cap $4.37M · Vol 86.76K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$4.37M

Micro Cap

Div Yield

N/A

EPS Growth

+52.13%

YoY

RSI (14)

16.00

Momentum

Beta

2.92

vs Market

52W High

$38.60

95.34% below

52W Low

$1.56

15.38% above

Volume

86.76K

Avg 48.07K

P/B

2.34

Price-to-book

ROE

N/A

Return on equity

Free Float

93.55%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Curis Inc (CRIS) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does CRIS pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-55.22%

-61.29%

-82.47%

-92.17%

YTD

-90.88%

-94.64%

-99.27%

-99.94%

Financials & Valuation

TTM · Annual

Total Revenue	$9.44M
Net Income	$-7,582,000.00
Revenue Growth (YoY)	-100.00%
Gross Margin	76.38%
Operating Margin	-371.57%
Net Profit Margin	-80.29%
ROE	N/A
ROA · ROIC	-24.77% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	1.38
P/B	2.34
P/FCF	N/A
EPS Growth	+52.13%
Outstanding Shares	2.43M

Technical Indicators

50-Day SMA	$5.92
200-Day SMA	$15.19
RSI (14)	16.00
Beta	2.92
52-Week High	$38.60
52-Week Low	$1.56

Volume Today	86.76K
Avg Daily Volume (30D)	48.07K
Relative Volume	1.80x
Volatility (10D)	252.03
Volatility (30D)	174.39
Free Float	93.55%

Analyst Consensus

BUY

Current Price $1.80

Mean Target $141.67

52W Low$1.56 52W High$38.60

Current

Target

$1.56 $38.60

Current Analyst target

+7,770.37% upside potential · 4 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001SFR6R1

ISINUS2312693094

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateAug 14, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -1.78% RVMD Revolution Medicines Inc +0.85% ONC BeOne Medicines AG -2.40% 068270.KS Celltrion Inc -0.50% ABVX Abivax SA -2.05%

Company Profile

Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). The Erivedge, is a commercialized orally administered small molecule Hedgehog signaling pathway antagonist. Its other clinical programs include Fimepinostat and CA-170. CA-170 is an oral small molecule drug candidate that targets V-domain Ig Suppressor of T-cell Activation, or VISTA, and PDL1 immune checkpoint proteins.